This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: November 21, 2008
Last updated: July 16, 2012
Last verified: July 2012

The primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according to the dose limiting toxicities (DLTs) observed when administered as a single agent once weekly.

Secondary objectives are:

  • to characterize the global safety profile
  • to evaluate the pharmacokinetic (PK) profile of SAR3419 in the proposed dosing schedule
  • to assess preliminary evidence of anti-lymphoma activity.

Condition Intervention Phase
Lymphoma Non-Hodgkin Drug: SAR3419 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma (NHL)

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Incidence of DLT(s) at each dose level [ Time Frame: during the initial 3-week period of treatment ]

Secondary Outcome Measures:
  • Cumulative DLT(s) [ Time Frame: over the entire period of treatment ]
  • Incidence of Adverse Events and laboratory abnormalities [ Time Frame: study period ]
  • Tumor response (complete response, partial response) and duration of the response [ Time Frame: study period ]
  • Pharmacokinetics parameters [ Time Frame: Study period ]

Enrollment: 77
Study Start Date: October 2008
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SAR3419
    administered by intravenous infusion

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of B-cell non Hodgkin's lymphoma
  • Relapsed or refractory after standard treatments and with no curative option with conventional therapy (Patients having undergone stem cell transplantation may be included)
  • CD19 positive disease by flow cytometry or immunohistochemistry

Exclusion Criteria:

  • Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia (Small lymphocytic lymphoma may be included)
  • Evidence of cerebral or meningeal involvement by lymphoma
  • Patients without bi-dimensionally measurable disease
  • ECOG performance status > 2
  • Life expectancy less than 3 months
  • Chemotherapy or radiation therapy or other investigational agents within 4 weeks prior to entering the study
  • Previous radioimmunotherapy within 12 weeks
  • Known anaphylaxis to infused proteins
  • HIV, HBV and HCV positivity
  • Poor kidney, liver and bone marrow functions
  • Any serious active disease or co-morbid condition, which, in the opinion of the principle investigator, will interfere with the safety or the compliance with the study
  • Pregnant or breast-feeding women
  • Patients with reproductive potential without effective birth control methods

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00796731

Sanofi-Aventis Investigational Site Number 250004
Creteil Cedex, France, 94010
Sanofi-Aventis Investigational Site Number 250006
Lille Cedex, France, 59037
Sanofi-Aventis Investigational Site Number 250001
Pierre Benite Cedex, France, 69495
Sanofi-Aventis Investigational Site Number 250005
Rennes, France, 35033
Sanofi-Aventis Investigational Site Number 250003
Rouen Cedex, France, 76038
Sanofi-Aventis Investigational Site Number 250002
Villejuif Cedex, France, 94805
Sponsors and Collaborators
Principal Investigator: Bertrand COIFFIER, Professor of Hematology Centre Hospitalier Lyon Sud, France
  More Information

Responsible Party: Sanofi Identifier: NCT00796731     History of Changes
Other Study ID Numbers: TED6829
EudraCT 2007-004868-41
Study First Received: November 21, 2008
Last Updated: July 16, 2012

Keywords provided by Sanofi:
B-cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 21, 2017